Isogenica's latest short video explains why targeted LNPs are now a major focus for oncology, neurology and immune applications — and how surface-attached targeting moieties could change that.
RNA medicine's progress has run in parallel with advances in lipid nanoparticle (LNP) delivery. But current LNP systems share a common limitation: they naturally home to the liver. That's useful for liver-targeted therapies, but a significant obstacle for oncology, neurological disease and immune modulation, where the payload needs to reach cells elsewhere in the body.
In this short video, Isogenica — The VHH Company — sets out why precision targeting has become one of the field's defining questions, and outlines the core strategy being explored: attaching a targeting moiety to the LNP surface to direct it towards specific cell types or tissues.
Watch the full video here: https://www.youtube.com/watch?v=QmJ7jS75qyw
